Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial

被引：0

作者：

Holmes, Frankie Ann ^{[1
]}

Moy, Beverly ^{[2
]}

Delaloge, Suzette ^{[3
]}

Chia, Stephen ^{[4
]}

Ejlertsen, Bent ^{[5
]}

Mansi, Janine ^{[6
,7
]}

Iwata, Hiroji ^{[8
]}

Gnant, Michael ^{[9
]}

Buyse, Mark ^{[10
]}

Barrios, Carlos ^{[11
]}

Silovski, Tajana ^{[12
]}

Separovic, Robert ^{[13
]}

Bashford, Anna ^{[14
]}

Guerrero-Zotano, Angel ^{[15
]}

Denduluri, Neelima ^{[16
]}

Patt, Debra ^{[17
]}

Gokmen, Erhan ^{[18
]}

Gore, Ira ^{[19
]}

Smith, John ^{[20
]}

Bryce, Richard ^{[21
]}

Xu, Feng ^{[22
]}

Wong, Alvin ^{[22
]}

Martin, Miguel ^{[23
]}

Chan, Arlene ^{[24
]}

机构：

[1] US Oncol, Texas Oncol, Houston, TX USA

[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[3] Int Gustave Roussy, Villejuif, France

[4] Univ British Columbia, British Columbia Canc Agcy, Vancouver, BC, Canada

[5] Univ Copenhagen, Copenhagen, Denmark

[6] Guys & St Thomas NHS Fdn Trust, London, England

[7] Kings Coll London, Biomed Res Ctr, London, England

[8] Aichi Canc Ctr Hosp, Chikusa Ku, Nagoya, Aichi, Japan

[9] Med Univ Vienna, Vienna, Austria

[10] Int Drug Dev Inst, San Francisco, CA USA

[11] Pontificia Univ Catolica Rio Grande do Sul, Ctr Pesquisa Oncol HSL, Porto Alegre, RS, Brazil

[12] UHC Sestre milosrdnice, Univ Hosp Tumors, Zagreb, Croatia

[13] Sestre Milosrdnice Univ Hosp Ctr, Univ Hosp Tumors, Zagreb, Croatia

[14] Auckland Hosp, Auckland, New Zealand

[15] Fdn Inst Valenciano Oncol, Valencia, Spain

[16] Virginia Canc Specialists, Arlington, VA USA

[17] Texas Oncol, Austin, TX USA

[18] Ege Univ, Fac Med, Izmir, Turkey

[19] Alabama Oncol, Birmingham, AL USA

[20] Compass Oncol, Portland, OR USA

[21] Puma Biotechnol Inc, Los Angeles, CA USA

[22] Puma Biotechnol Inc, San Francisco, CA USA

[23] Univ Complutense Madrid, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain

[24] Perth & Curtin Univ, Breast Canc Res Ctr WA, Nedlands, WA, Australia

来源：

CANCER RESEARCH | 2021年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PD3-03

引用

页数：1

共 50 条

[1] Continued Efficacy of Neratinib in Patients With HER2-Positive Early-Stage Breast Cancer: Final Overall Survival Analysis From the Randomized Phase 3 ExteNET Trial
不详
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 17 - 17
[2] Continued Efficacy of Neratinib in Patients With HER2-Positive Early-Stage Breast Cancer: Final Overall Survival Analysis From the Randomized Phase 3 ExteNET Trial
不详
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 5 - 6
[3] Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial
Martin, M.
Holmes, F. A.
Moy, B.
Mansi, J.
Gnant, M.
Buyse, M.
Barrios, C.
Bryce, R.
Wong, A.
Chan, A.
[J]. BREAST, 2021, 56 : S19 - S19
[4] Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
Chan, Arlene
Moy, Beverly
Mansi, Janine
Ejlertsen, Bent
Holmes, Frankie Ann
Chia, Stephen
Iwata, Hiroji
Gnant, Michael
Loibl, Sibylle
Barrios, Carlos H.
Somali, Isil
Smichkoska, Snezhana
Martinez, Noelia
Alonso, Mirta Garcia
Link, John S.
Mayer, Ingrid A.
Cold, Soren
Murillo, Serafin Morales
Senecal, Francis
Inoue, Kenichi
Ruiz-Borrego, Manuel
Hui, Rina
Denduluri, Neelima
Patt, Debra
Rugo, Hope S.
Johnston, Stephen R. D.
Bryce, Richard
Zhang, Bo
Xu, Feng
Wong, Alvin
Martin, Miguel
[J]. CLINICAL BREAST CANCER, 2021, 21 (01) : 80 - +
[5] Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III ExteNET trial
Chan, A.
Moy, B.
Mansi, J. L.
Gnant, M. I.
Barrios, C. H.
Separovic, R.
Guerrero-Zotano, A.
Gore, I.
Smith, J.
Bryce, R. P.
Xu, F.
Wong, A.
Martin, M.
Holmes, F. A.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S40 - S40
[6] Neratinib in Early-Stage HER2-Positive Breast Cancer
Cherian, Mathew A.
Ma, Cynthia X.
[J]. BREAST DISEASES, 2015, 26 (04): : 285 - 287
[7] Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Earlystage Breast Cancer From the Phase III ExteNET Trial
Lichert, Frank
[J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (05)
[8] Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
Barcenas, C. H.
Hurvitz, S. A.
Di Palma, J. A.
Bose, R.
Chien, A. J.
Iannotti, N.
Marx, G.
Brufsky, A.
Litvak, A.
Ibrahim, E.
Alvarez, R. H.
Ruiz-Borrego, M.
Chan, N.
Manalo, Y.
Kellum, A.
Trudeau, M.
Thirlwell, M.
Saenz, J. Garcia
Hunt, D.
Bryce, R.
McCulloch, L.
Rugo, H. S.
Tripathy, D.
Chan, A.
[J]. ANNALS OF ONCOLOGY, 2020, 31 (09) : 1223 - 1230
[9] Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial
Delaloge, S.
Cella, D.
Ye, Y.
Buyse, M.
Chan, A.
Barrios, C. H.
Holmes, F. A.
Mansi, J.
Iwata, H.
Ejlertsen, B.
Moy, B.
Chia, S. K. L.
Gnant, M.
Smichkoska, S.
Ciceniene, A.
Martinez, N.
Filipovic, S.
Ben-Baruch, N. E.
Joy, A. A.
Langkjer, S. T.
Senecal, F.
de Boer, R. H.
Moran, S.
Yao, B.
Bryce, R.
Auerbach, A.
Fallowfield, L.
Martin, M.
[J]. ANNALS OF ONCOLOGY, 2019, 30 (04) : 567 - 574
[10] Improved central nervous system outcomes in patients with early-stage HER2-positive breast cancer who receive neratinib for the recommended duration: Findings from the phase 3 ExteNET trial
Holmes, Frankie Ann
Patt, Debra
Manalo, Yvonne
Smith, Julie C.
Papish, Steven W.
Efrat, Noa
Arance, Ana
Zhang, Bo
Lalla, Deepa
Wong, Alvin
Martin, Miguel
[J]. CANCER RESEARCH, 2022, 82 (04)

← 1 2 3 4 5 →